David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(14):1313-1327. 3 National Cancer Institute. NCI dictionary - small cell lung cancer.

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European ...

Patients with solid tumor malignancies had better survival after ICI therapy if they were obese than if they had a normal BMI.

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

The FDA granted approval for the use of Skytrofa (lonapegsomatropin) in September 2021 for the treatment of pediatric ...

Market capitalisation stands at Rs 19,771.25 crore. The share touched a 52-week high of Rs 9,049.95 and a 52-week low of Rs 5 ...

The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label ...

AstraZeneca‘s IMFINZI® (durvalumab) has gained FDA approval for use in adult patients with muscle-invasive bladder cancer ...

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] Draft guidance Technology appraisal guidance 29 ...